Alnylam Pharmaceuticals Inc

This innovative biotech stock has helped transform RNAi into an innovative new class of medicine. You have probably heard about RNA and mRNA innovation as the basis for the COVID-19 vaccine. This novel technology is set to shake up the medical world, and Alnylam is well-positioned to benefit from it.

$297.14
(as of Oct 17, 3:56 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Alnylam Pharmaceuticals Inc

Stock Price
$297.15
Ticker Symbol
ALNY
Exchange
NASDAQ

Industry Information for Alnylam Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Alnylam Pharmaceuticals Inc

Website
https://www.alnylam.com
Country
USA
Full Time Employees
2,100

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Fundamentals for Alnylam Pharmaceuticals Inc

Market Capitalization
$38,097,059,840
EBITDA
$157,972,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
714.29
Earnings per Share
$-0.57
Earnings per Share Estimate Next Year
$-1.49
Profit Margin
-3.11%
Shares Outstanding
128,381,000
Percent Owned by Insiders
0.42%
Percent Owned by Institutions
96.05%
52-Week High
$304.39
52-Week Low
$141.98

Technical Indicators for Alnylam Pharmaceuticals Inc

50-Day Moving Average
$271.45
200-Day Moving Average
$201.07
RSI
70.25
ATR
7.93

Analyst Ratings for Alnylam Pharmaceuticals Inc

Strong Buy
11
Buy
11
Hold
8
Sell
1
Strong Sell
0

News About Alnylam Pharmaceuticals Inc

Oct 16, 2024, 8:00 AM EST
− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – See more.
Oct 15, 2024, 9:01 AM EST
Shares of Repare Therapeutics RPTX gained 8% on Monday after it announced dosing the first patient in an early-stage study evaluating the combination regimen of its Polθ ATPase inhibitor, RP-3467, and AstraZeneca’s AZN Lynparza (olaparib), a leading PARP inhibitor, to treat several advanced solid tumors. See more.
Oct 11, 2024, 7:08 AM EST
As the U.S. stock market navigates the complexities of inflation and employment data, investors are increasingly attentive to economic indicators that influence Federal Reserve policies and interest rate decisions. See more.
Oct 9, 2024, 12:14 PM EST
Alnylam stock is in flat base and is offering a potential early entry. See more.
Oct 9, 2024, 9:33 AM EST
Shares of Soleno Therapeutics SLNO jumped 9.1% on Tuesday and continued to gain another 4.1% during the after-market hours following a positive regulatory update on its new drug application (NDA) seeking approval for DCCR (diazoxide choline) extended-release tablets to treat Prader-Willi syndrome (PWS). See more.